Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses

Parkinsonism and Related Disorders

Volumn 23, Issue , 2016, Pages 1-9

  Bellou, Vanesa ^a   Belbasis, Lazaros ^a   Tzoulaki, Ioanna ^a,b   Evangelou, Evangelos ^a,b   Ioannidis, John P A ^c,d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Environment; Epidemiology; Meta analysis; Parkinson's disease; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYANOCOBALAMIN; HYDROCARBON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC SOLVENT; PESTICIDE; PYRIDOXINE; URIC ACID; VITAMIN D; WELL WATER; XANTHOPHYLL;

AGRICULTURAL WORKER; ALCOHOL CONSUMPTION; ANXIETY; BONE DENSITY; CALORIC INTAKE; CAUSAL ATTRIBUTION; COFFEE; COMORBIDITY; CONSTIPATION; DAIRY PRODUCT; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAT INTAKE; FLUID INTAKE; GENETIC HETEROGENEITY; HABIT; HEAD INJURY; HUMAN; MEDICAL HISTORY; OBSERVATIONAL STUDY; PARKINSON DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RURAL POPULATION; SMOKING; SYSTEMATIC ERROR; SYSTEMATIC REVIEW (TOPIC); TEA; URIC ACID BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; WELDING; META ANALYSIS (TOPIC);

ENVIRONMENTAL EXPOSURE; HUMANS; META-ANALYSIS AS TOPIC; PARKINSON DISEASE; RISK FACTORS;

EID: 84953291577     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.12.008     Document Type: Review

References (104)

1. De Lau L.M.L., Breteler M.M.B. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535. 10.1016/S1474-4422(06)70471-9.
2. Pringsheim T., Jette N., Frolkis A., Steeves T.D.L. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 2014, 29:1583-1590. 10.1002/mds.25945.
3. Kowal S.L., Dall T.M., Chakrabarti R., Storm M.V., Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 2013, 28:311-318. 10.1002/mds.25292.
4. Nalls M.A., McLean C.Y., Rick J., Eberly S., Hutten S.J., Gwinn K., et al. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 2015, 14:1002-1009. 10.1016/S1474-4422(15)00178-7.
5. Lill C.M., Roehr J.T., McQueen M.B., Kavvoura F.K., Bagade S., Schjeide B.-M.M., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 2012, 8:e1002548. 10.1371/journal.pgen.1002548.
6. Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 2014, 46:989-993. 10.1038/ng.3043.
7. Ioannidis J.P.A. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009, 181:488-493. 10.1503/cmaj.081086.
8. Belbasis L., Bellou V., Evangelou E., Ioannidis J.P.A., Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015, 14:263-273. 10.1016/S1474-4422(14)70267-4.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
10. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 1997, 127:820-826.
11. Higgins J.P.T., Thompson S.G., Spiegelhalter D.J. A re-evaluation of random-effects meta-analysis. J. R. Stat. Soc. Ser. A Stat. Soc. 2009, 172:137-159. 10.1111/j.1467-985X.2008.00552.x.
12. Higgins J.P.T. Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int. J. Epidemiol. 2008, 37:1158-1160. 10.1093/ije/dyn204.
13. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat. Med. 2000, 19:3127-3131.
14. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101. 10.2307/3001666.
15. Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558. 10.1002/sim.1186.
16. Sterne J.A.C., Sutton A.J., Ioannidis J.P.A., Terrin N., Jones D.R., Lau J., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002.
17. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
18. Ioannidis J.P.A., Trikalinos T.A. An exploratory test for an excess of significant findings. Clin. Trials 2007, 4:245-253. 10.1177/1740774507079441.
19. Ioannidis J.P.A. Clarifications on the application and interpretation of the test for excess significance and its extensions. J. Math. Psychol. 2013, 57:184-187. 10.1016/j.jmp.2013.03.002.
20. Lubin J.H., Gail M.H. On power and sample size for studying features of the relative odds of disease. Am. J. Epidemiol. 1990, 131:552-566.
21. Van der Mark M., Brouwer M., Kromhout H., Nijssen P., Huss A., Vermeulen R. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ. Health Perspect. 2012, 120:340-347. 10.1289/ehp.1103881.
22. Noyce A.J., Bestwick J.P., Silveira-Moriyama L., Hawkes C.H., Giovannoni G., Lees A.J., et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 2012, 72:893-901. 10.1002/ana.23687.
23. Pezzoli G., Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013, 80:2035-2041. 10.1212/WNL.0b013e318294b3c8.
24. Cereda E., Barichella M., Pedrolli C., Klersy C., Cassani E., Caccialanza R., et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care 2011, 34:2614-2623. 10.2337/dc11-1584.
25. Lu L., Fu D.-L., Li H.-Q., Liu A.-J., Li J.-H., Zheng G.-Q. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One 2014, 9:e85781. 10.1371/journal.pone.0085781.
26. Ioannidis J.P.A., Tarone R., McLaughlin J.K. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 2011, 22:450-456. 10.1097/EDE.0b013e31821b506e.
27. Johnson V.E. Revised standards for statistical evidence. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19313-19317. 10.1073/pnas.1313476110.
28. Allam M.F., Campbell M.J., Del Castillo A.S., Fernández-Crehuet Navajas R. Parkinson's disease protects against smoking?. Behav. Neurol. 2004, 15:65-71.
29. Allam M.F., Campbell M.J., Hofman A., Del Castillo A.S., Fernández-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord. 2004, 19:614-621. 10.1002/mds.20029.
30. Allam M.F., del Castillo A.S., Navajas R.F.-C. Parkinson's disease, tobacco and age: meta analysis. Rev. Neurol. 2003, 36:510-513.
31. Allam M.F., Del Castillo A.S., Navajas R.F.-C. Parkinson's disease, smoking and family history: meta-analysis. Eur. J. Neurol. 2003, 10:59-62.
32. Allam M.F., Serrano del Castillo A., Fernández-Crehuet Navajas R. Smoking and Parkinson's disease: explanatory hypothesis. Int. J. Neurosci. 2002, 112:851-854.
33. Ritz B., Ascherio A., Checkoway H., Marder K.S., Nelson L.M., Rocca W.A., et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch. Neurol. 2007, 64:990-997. 10.1001/archneur.64.7.990.
34. Hernán M.A., Takkouche B., Caamaño-Isorna F., Gestal-Otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 2002, 52:276-284. 10.1002/ana.10277.
35. Sugita M., Izuno T., Tatemichi M., Otahara Y. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. J. Epidemiol. 2001, 11:87-94.
36. Kiyohara C., Kusuhara S. Cigarette smoking and Parkinson's disease: a meta-analysis. Fukuoka Igaku Zasshi 2011, 102:254-265.
37. Allen M.T., Levy L.S. Parkinson's disease and pesticide exposure-a new assessment. Crit. Rev. Toxicol. 2013, 43:515-534. 10.3109/10408444.2013.798719.
38. Priyadarshi A., Khuder S.A., Schaub E.A., Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ. Res. 2001, 86:122-127. 10.1006/enrs.2001.4264.
39. Priyadarshi A., Khuder S.A., Schaub E.A., Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000, 21:435-440.
40. Van Maele-Fabry G., Hoet P., Vilain F., Lison D. Occupational exposure to pesticides and Parkinson's disease: a systematic review and meta-analysis of cohort studies. Environ. Int. 2012, 46:30-43. 10.1016/j.envint.2012.05.004.
41. Freire C., Koifman S. Pesticide exposure and Parkinson's disease: epidemiological evidence of association. Neurotoxicology 2012, 33:947-971. 10.1016/j.neuro.2012.05.011.
42. Hamer M., Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol. Med. 2009, 39:3-11. 10.1017/S0033291708003681.
43. Xu Q., Park Y., Huang X., Hollenbeck A., Blair A., Schatzkin A., et al. Physical activities and future risk of Parkinson disease. Neurology 2010, 75:341-348. 10.1212/WNL.0b013e3181ea1597.
44. Costa J., Lunet N., Santos C., Santos J., Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J. Alzheimers Dis. 2010, 20:S221-S238. 10.3233/JAD-2010-091525.
45. Liu R., Guo X., Park Y., Huang X., Sinha R., Freedman N.D., et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am. J. Epidemiol. 2012, 175:1200-1207. 10.1093/aje/kwr451.
46. Samii A., Etminan M., Wiens M.O., Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26:769-779. 10.2165/11316780-000000000-00000.
47. Torsney K.M., Noyce A.J., Doherty K.M., Bestwick J.P., Dobson R., Lees A.J. Bone health in Parkinson's disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2014, 85:1159-1166. 10.1136/jnnp-2013-307307.
48. Kamel F., Goldman S.M., Umbach D.M., Chen H., Richardson G., Barber M.R., et al. Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat. Disord. 2014, 20:82-87. 10.1016/j.parkreldis.2013.09.023.
49. Van der Marck M.A., Dicke H.C., Uc E.Y., Kentin Z.H.A., Borm G.F., Bloem B.R., et al. Body mass index in Parkinson's disease: a meta-analysis. Parkinsonism Relat. Disord. 2012, 18:263-267. 10.1016/j.parkreldis.2011.10.016.
50. Gao L., Tang H., Nie K., Wang L., Zhao J., Gan R., et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci. 2015, 125:645-654. 10.3109/00207454.2014.961454.
51. Adams-Carr K.L., Bestwick J.P., Shribman S., Lees A., Schrag A., Noyce A.J. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2015, jnnp - 2015-311680. 10.1136/jnnp-2015-311680.
52. Yang F., Trolle Lagerros Y., Bellocco R., Adami H.-O., Fang F., Pedersen N.L., et al. Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain 2015, 138:269-275. 10.1093/brain/awu323.
53. Jafari S., Etminan M., Aminzadeh F., Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov. Disord. 2013, 28:1222-1229. 10.1002/mds.25458.
54. Shen L., Ji H.-F. Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis. BMJ Open 2013, 3:e003620. 10.1136/bmjopen-2013-003620.
55. Lau J., Ioannidis J.P.A., Terrin N., Schmid C.H., Olkin I. The case of the misleading funnel plot. BMJ Br. Med. J. 2006, 333:597-600. 10.1136/bmj.38946.501215.68.
56. Tanner C.M., Comella C.L. When brawn benefits brain: physical activity and Parkinson's disease risk. Brain 2015, 138:238-239. 10.1093/brain/awu351.
57. Palma J.-A., Kaufmann H. Autonomic disorders predicting Parkinson's disease. Parkinsonism Relat. Disord. 2014, 20:S94-S98. 10.1016/S1353-8020(13)70024-5.
58. Braak H., De Vos R.A.I., Bohl J., Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 2006, 396:67-72. 10.1016/j.neulet.2005.11.012.
59. Beach T.G., Adler C.H., Sue L.I., Vedders L., Lue L.F., White C.L., et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119:689-702. 10.1007/s00401-010-0664-3.
60. Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start?. Arch. Neurol. 2010, 67:798-801. 10.1001/archneurol.2010.135.
61. Wirdefeldt K., Adami H.-O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26:S1-S58. 10.1007/s10654-011-9581-6.
62. Van der Mark M., Nijssen P.C.G., Vlaanderen J., Huss A., Mulleners W.M., Sas A.M.G., et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking. PLoS One 2014, 9:e95297. 10.1371/journal.pone.0095297.
63. Ritz B., Lee P.-C., Lassen C.F., Arah O.A. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014, 83:1396-1402. 10.1212/WNL.0000000000000879.
64. Gao X., Chen H., Schwarzschild M.A., Logroscino G., Ascherio A. Perceived imbalance and risk of Parkinson's disease. Mov. Disord. 2008, 23:613-616. 10.1002/mds.21919.
65. Rugbjerg K., Ritz B., Korbo L., Martinussen N., Olsen J.H. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ 2008, 337:a2494.
66. Aarsland D., Påhlhagen S., Ballard C.G., Ehrt U., Svenningsson P. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat. Rev. Neurol. 2012, 8:35-47. 10.1038/nrneurol.2011.189.
67. Ascherio A., LeWitt P.A., Xu K., Eberly S., Watts A., Matson W.R., et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 2009, 66:1460-1468. 10.1001/archneurol.2009.247.
68. Ungprasert P., Srivali N., Thongprayoon C. Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat. Disord. 2015, 21:1238-1242. 10.1016/j.parkreldis.2015.08.030.
69. Cheng H.-C., Ulane C.M., Burke R.E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 2010, 67:715-725. 10.1002/ana.21995.
70. Lang A.E. In pursuit of prodromal Parkinson's disease. Lancet Neurol. 2015, 14:27-28. 10.1016/S1474-4422(14)70230-3.
71. Schrag A., Horsfall L., Walters K., Noyce A., Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2015, 14:57-64. 10.1016/S1474-4422(14)70287-X.
72. Lo C.K.-L., Mertz D., Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med. Res. Methodol. 2014, 14:45. 10.1186/1471-2288-14-45.
73. Hartling L., Milne A., Hamm M.P., Vandermeer B., Ansari M., Tsertsvadze A., et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J. Clin. Epidemiol. 2013, 66:982-993. 10.1016/j.jclinepi.2013.03.003.
74. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25:603-605. 10.1007/s10654-010-9491-z.
75. Huang H.-C., Tsai C.-H., Muo C.-H., Lin K.-H., Lu M.-K., Sung F.-C., et al. Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study. J. Clin. Psychiatry 2015, 76. e104-10. 10.4088/JCP.13m08790.
76. Wang I.-K., Lin C.-L., Wu Y.-Y., Chou C.-Y., Lin S.-Y., Liu J.-H., et al. Increased risk of Parkinson's disease in patients with end-stage renal disease: a retrospective cohort study. Neuroepidemiology 2014, 42:204-210. 10.1159/000358921.
77. Goldman S.M. Environmental toxins and Parkinson's disease. Annu. Rev. Pharmacol. Toxicol. 2014, 54:141-164. 10.1146/annurev-pharmtox-011613-135937.
78. Berg D., Godau J., Seppi K., Behnke S., Liepelt-Scarfone I., Lerche S., et al. The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur. J. Neurol. 2013, 20:102-108. 10.1111/j.1468-1331.2012.03798.x.
79. Zhang D., Jiang H., Xie J. Alcohol intake and risk of Parkinson's disease: a meta-analysis of observational studies. Mov. Disord. 2014, 29:819-822. 10.1002/mds.25863.
80. Shen L., Ji H.-F. Associations between vitamin D status, supplementation, outdoor work and risk of Parkinson's disease: a meta-analysis assessment. Nutrients 2015, 7:4817-4827. 10.3390/nu7064817.
81. Li F.-J., Ji H.-F., Shen L. A meta-analysis of tea drinking and risk of Parkinson's disease. Sci. World J. 2012, 2012:1-6. 10.1100/2012/923464.
82. Huss A., Koeman T., Kromhout H., Vermeulen R. Extremely low frequency magnetic field exposure and Parkinson's disease-a systematic review and meta-analysis of the data. Int. J. Environ. Res. Public Health 2015, 12:7348-7356. 10.3390/ijerph120707348.
83. Mortimer J.A., Borenstein A.R., Nelson L.M. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology 2012, 79:1174-1180. 10.1212/WNL.0b013e3182698ced.
84. Palin O., Herd C., Morrison K.E., Jagielski A.C., Wheatley K., Thomas G.N., et al. Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease. Parkinsonism Relat. Disord. 2015, 21:243-248. 10.1016/j.parkreldis.2014.12.017.
85. Etminan M., Gill S.S., Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. 2005, 4:362-365. 10.1016/S1474-4422(05)70097-1.
86. Jiang W., Ju C., Jiang H., Zhang D. Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur. J. Epidemiol. 2014, 29:613-619. 10.1007/s10654-014-9921-4.
87. Shen L. Associations between B vitamins and Parkinson's disease. Nutrients 2015, 7:7197-7208. 10.3390/nu7095333.
88. Takeda A., Nyssen O.P., Syed A., Jansen E., Bueno-de-Mesquita B., Gallo V. Vitamin A and carotenoids and the risk of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 2014, 42:25-38. 10.1159/000355849.
89. Wang A., Lin Y., Wu Y., Zhang D. Macronutrients intake and risk of Parkinson's disease: a meta-analysis. Geriatr. Gerontol. Int. 2015, 15:606-616. 10.1111/ggi.12321.
90. Liu R., Gao X., Lu Y., Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011, 76:2002-2009. 10.1212/WNL.0b013e31821e554e.
91. Gagne J.J., Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74:995-1002. 10.1212/WNL.0b013e3181d5a4a3.
92. Gao X., Chen H., Schwarzschild M.A., Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011, 76:863-869. 10.1212/WNL.0b013e31820f2d79.
93. Lang Y., Gong D., Fan Y. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. Pharmacoepidemiol. Drug Saf. 2015, 24:559-566.
94. Undela K., Gudala K., Malla S., Bansal D. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J. Neurol. 2013, 260:158-165. 10.1007/s00415-012-6606-3.
95. Wang P., Li J., Qiu S., Wen H., Du J. Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies. Neuropsychiatr. Dis. Treat. 2015, 11:59-66. 10.2147/NDT.S69918.
96. Chen J., Guan Z., Wang L., Song G., Ma B., Wang Y. Meta-analysis: overweight, obesity, and Parkinson's disease. Int. J. Endocrinol. 2014, 2014:1-7. 10.1155/2014/203930.
97. Gudala K., Bansal D., Muthyala H. Role of serum cholesterol in Parkinson's disease: a meta-analysis of evidence. Parkinson's Dis. 2013, 3:363-370. 10.3233/JPD-130196.
98. Lv Z., Qi H., Wang L., Fan X., Han F., Wang H., et al. Vitamin D status and Parkinson's disease: a systematic review and meta-analysis. Neurol. Sci. 2014, 35:1723-1730. 10.1007/s10072-014-1821-6.
99. Mariani S., Ventriglia M., Simonelli I., Donno S., Bucossi S., Vernieri F., et al. Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol. Aging 2013, 34:632-633. 10.1016/j.neurobiolaging.2012.05.015.
100. Sako W., Murakami N., Izumi Y., Kaji R. MRI can detect nigral volume loss in patients with Parkinson's disease: evidence from a meta-analysis. J. Parkinson's Dis. 2014, 4:405-411. 10.3233/JPD-130332.
101. Shen C., Guo Y., Luo W., Lin C., Ding M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can. J. Neurol. Sci. 2013, 40:73-79.
102. Wang Y.-L., Wang Y.-T., Li J.-F., Zhang Y.-Z., Yin H.-L., Han B. Body mass index and risk of Parkinson's disease: a dose-response meta-analysis of prospective studies. PLoS One 2015, 10:e0131778. 10.1371/journal.pone.0131778.
103. Yu J.-G., Feng Y.-F., Xiang Y., Huang J.-H., Savini G., Parisi V., et al. Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS One 2014, 9:e85718. 10.1371/journal.pone.0085718.
104. Zhao Y., Shen L., Ji H.-F. Osteoporosis risk and bone mineral density levels in patients with Parkinson's disease: a meta-analysis. Bone 2013, 52:498-505. 10.1016/j.bone.2012.09.013.